Severe acute respiratory syndrome (SARS) is caused by a newly identified human coronavirus named SARS coronavirus (SARS-CoV). Viral entry is one of the most important early events in the replication cycle of a coronavirus. Previous studies have demonstrated that the spike (S) protein of SARS-CoV binds specifically to the human angiotensin-converting enzyme 2 (ACE2) receptor, and mediates the viral entry into host cells. In this study, we first constructed and produced the S-protein pseudotyped viruses that carry the luciferase reporter gene, and confirmed that the viral entry was dependent on the human ACE2 receptor. We subsequently infected a variety of human cell lines with the pseudopyted virus, and found that human Huh-7 cells are highly permissive to the pseudopyted viral infection. To develop an assay for high throughput screening (HTS), we further optimized this viral entry assay in 96-well plate format, and demonstrated that soluble human ACE2 protein or anti-human ACE2 antibodies could potently block the S-ACE2 mediated viral entry. We are currently employing this sensitive and quantitative viral entry assay to screen a small molecule library consisting of 190,000 compounds at McMaster HTS Laboratory to identify novel molecules that may disrupt the S-ACE2 interaction and block viral entry of SARS-CoV.
